11 Good Energy, Inc. ELVN 深 沪
已收盘 12-19 16:00:00 美东时间
16.87
+0.190
+1.14%
华盛通- 最 高17.15
- 今 开16.71
- 成交量 122.33万股
- 最 低 16.605
- 昨 收 16.68
- 总市值 10.01亿
- 52周最高 25.37
- 市盈率 静 --
- 换手率 2.06%
- 52周最低 13.30
- 委 比 -48.51%
- 总股本 5934.73万
- 历史最高 250.84
- 量 比 1.06
- 振 幅 3.27%
- 历史最低 3.896
- 每 手 1
- 风险率 1.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股周涨跌榜 | “减肥神药”临床数据引爆！WaVe生命科学周涨121%；太空概念股Planet Labs周涨42.8%
“减肥神药”临床数据引爆！WaVe生命科学周涨121%；福尼克斯周内飙升50%，创历史新高；SpaceX上市传闻引爆市场，太空概念股Planet Labs周涨42.8%>>
12-13 10:07
Enliven Therapeutics Appoints Rick Fair As CEO And Member Of Board Of Directors, Effective Immediately
Rick Fair, a seasoned executive with deep experience developing and commercializing hematology products, joins Enliven as Chief Executive OfficerCo-Founder Sam Kintz will assume a new position as Head of PipelineBOULDER,
12-11 22:04
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster
Terns Pharma presented positive data from ongoing CARDINAL trial of TERN-701 in CML patients, showing high MMR rates and good safety profile.
12-09 20:51
Enliven's ELVN-001 Shows Anti-CML Activity In Patients With Atypical Fusion Transcripts; Will Present Data From The Ongoing ENABLE Phase 1a/1b Clinical Trial Of ELVN-001 On A Subset Of Chronic Myeloid LeukemiaPatients At The ASH 2025 Annual Meeting
ELVN-001 demonstrates encouraging anti-CML activity in heavily pretreated patients with atypical fusion transcriptsGrowing unmet need for patients with atypical transcript e13a3, which is resistant to TKIs targeting the
11-03 22:09
Enliven Therapeutics Q2 EPS $(0.49) Beats $(0.54) Estimate
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.54) by 9.26 percent. This is a 19.51 percent decrease over losses of $(0.41) per share
08-14 04:25
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Enliven Therapeutics (ELVN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
07-18 21:30
美股大行评级 | 潜在涨幅336.36%！Canaccord Genuity上调ATAI Life Sciences目标价至12美元，维持"买入"评级
Redburn Atlantic：下调Adobe(ADBE)评级至"卖出"，目标价从420美元降至280美元
07-03 11:01
HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $48
HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $40 to $48.
07-02 18:47
美股大行评级 | 超配！Hinge Health获多家大行首予评级； Oppenheimer上调Mate目标价从665美元升至775美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1141651881139785729.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持SurgePays Inc(SURG)"买入"评级，目标价从8.75美元升至9美元</p> <p>• Ascendiant Capital：维持LiqTech Internatio
06-17 09:46
